This report examines the impact of the reduction in VAT on sales of NRT
Author: Judy Davis Published By: ASH Published : 29/01/2007
NRT or Nicotine Replacement Therapies
In the UK, smokers wanting an aid to quitting can choose from a wide range of nicotine replacement therapies (NRT) including gum, patches and inhalers. NRT is a highly cost effective life-preserving intervention and is available from pharmacists on general sale or by prescription.
In 2005 the licensing arrangements for Nicotine Replacement Therapies (NRT) were changed to widen access to the therapies and remove some of the contra-indications that had previously been applied.
ASH supports these changes and produced guidance for health professionals, on these changes.
Nicotine Replacement Therapy - VAT reduction and sales of NRT
This report examines the impact of the reduction in VAT on sales of NRT
This report examines the impact of the reduction in VAT on sales of NRT
Nicotine Replacement Therapy: Guidance for health professionals on changes in the licensing arrangements for NRT
Nicotine Replacement Therapy: Guidance for health professionals on changes in the licensing arrangements for NRT
Nicotine Replacement Therapy: Guidance for health professionals on changes in the licensing arrangements for NRT
Author: ASH Published By: ASH Published : 28/12/2005
NRT: UK Marketing Review
This report commissioned by ASH aims to summarise the current NRT market in the UK, and to review current status from a consumer and trade perspective
This report commissioned by ASH aims to summarise the current NRT market in the UK, and to review current status from a consumer and trade perspective
Author: Judy Davis Published By: Judy Davis Marketing/ASH Published : 30/04/2005
Implementing NICE guidance - GlaxoSmithKline
A series of briefings and checklists aimed at health professionals for prescribing smoking cessation pharmaceutical products
A series of briefings and checklists aimed at health professionals for prescribing smoking cessation pharmaceutical products
Author: GlaxoSmithKline Published By: GlaxoSmithKline Published : 01/04/2002
Regulation of NRT: A critique of current practice
This journal article examine the main controversial applications of NRT use by young people, during pregnancy, by Cardio Heart Disease sufferers, for harm reduction, smoking reduction and as a recreational drug. In each case, there is an assessment of the evidence and a discussion of the appropriate approach - and a critique of the failure of regulators to tackle these issues adequately.
This journal article examine the main controversial applications of NRT use by young people, during pregnancy, by Cardio Heart Disease sufferers, for harm reduction, smoking reduction and as a recreational drug. In each case, there is an assessment of the evidence and a discussion of the appropriate approach - and a critique of the failure of regulators to tackle these issues adequately.
Author: Anne McNeill, Jonathan Foulds, Clive Bates Published By: Addiction Published : 30/11/2001
ASH summary position on NRT and Zyban for smoking cessation
Summary of views on smoking cessation drugs provided for the NICE Appraisal Committee's. Arguments are given from the smoker's perspective for mainstreaming these products in the NHS.
Summary of views on smoking cessation drugs provided for the NICE Appraisal Committee's. Arguments are given from the smoker's perspective for mainstreaming these products in the NHS.
Author: Clive Bates, Martin Jarvis Published By: ASH Published : 24/10/2001
ASH Submission to NICE on NRT and bupropion
ASH submission to the National Institute for Clinical Excellence (NICE) making the case for prescribing NRT and Zyban. We argue for an unrestrictive framework for prescribing, stressing the cost effectiveness - especially in comparison to other treatments, like statins. A good set of links to the supporting evidence is included. This is a joint effort by ASH, British Lung Foundation and Cancer Research Campaign
ASH submission to the National Institute for Clinical Excellence (NICE) making the case for prescribing NRT and Zyban. We argue for an unrestrictive framework for prescribing, stressing the cost effectiveness - especially in comparison to other treatments, like statins. A good set of links to the supporting evidence is included. This is a joint effort by ASH, British Lung Foundation and Cancer Research Campaign
Author: ASH, British Lung Foundation, Cancer Research UK Published By: ASH Published : 13/07/2001
Pharmacy Healthcare Scheme Press release
Quitting made easier as high street pharmacies offer nicotine replacement therapies on the NHS
Quitting made easier as high street pharmacies offer nicotine replacement therapies on the NHS
Author: Pharmacy Healthcare Scheme Published By: Pharmacy Healthcare Scheme Published : 20/06/2001
Statutory Instrument 2001 No 2068 List of products licenced for sale in any retail outlet
List of medicines (products other than veterinary drugs) General sales list Amendment order 2001. Lists those products that are licenced for sale in any retail outlet.
List of medicines (products other than veterinary drugs) General sales list Amendment order 2001. Lists those products that are licenced for sale in any retail outlet.
Author: HMSO Published By: Crown Copyright Published : 04/06/2001
Sample Patient Group Direction (PGD) allowing supply of NRT by health professionals other than doctors
This document from the Pharmacy Healthcare Scheme shows health professionals other than doctors can be authorised to supply NRT. The PGD establish permission to supply and a protocol under which the person who is supplying must act.
This document from the Pharmacy Healthcare Scheme shows health professionals other than doctors can be authorised to supply NRT. The PGD establish permission to supply and a protocol under which the person who is supplying must act.
Author: Pharmacy Healthcare Published By: Pharmacy Healthcare Published : 31/05/2001
ASH Letter to Medicines Control Agency - NRT and NHS perscriptions
Letter to Dugan Cummings, Medicines Control Agency that ASH supports the case for making more NRT products available for sale in any retail outlet.
Letter to Dugan Cummings, Medicines Control Agency that ASH supports the case for making more NRT products available for sale in any retail outlet.
Author: Clive Bates Published By: ASH Published : 31/01/2001
ASH Letter to Martin Glasspool on NRT being available on prescription
ASH endorsed the proposal to remove the Schedule 10 on NRT products so that they are percribably by GPs on the NHS.
ASH endorsed the proposal to remove the Schedule 10 on NRT products so that they are percribably by GPs on the NHS.
Author: Karen Richardson Published By: ASH Published : 15/01/2001
Letter on NRT and specialist services to smoking cessation co-ordinators
Following the National Plan, this clarifies the Department's intention to go out to consult about the deblacklisting of NRT and discusses implications for the smoking cessation services
Following the National Plan, this clarifies the Department's intention to go out to consult about the deblacklisting of NRT and discusses implications for the smoking cessation services
Author: Department of Health Published By: Department of Health Published : 30/06/2000
Satutory Instrument 1999 No 852 Products on general retail sale
The medicines (products other than veterniary drugs) on general sale Amendment order 1999. Regulations for medicines available on general sale.
The medicines (products other than veterniary drugs) on general sale Amendment order 1999. Regulations for medicines available on general sale.
Author: HMSO Published By: Crown Copyright Published : 06/04/1999
NRT in patients with cardiovascular disease: guidelines for health professionals
Guidance for health professionals on the use of NRT with heart disease suffers. The article stress the benefits of improving the chances of smoking cessation over any residual risk associated with NRT use.
Guidance for health professionals on the use of NRT with heart disease suffers. The article stress the benefits of improving the chances of smoking cessation over any residual risk associated with NRT use.
Report by the Office of Tobacco Control (Ireland) on Health Effects of ETS in the Workplace (pdf)
This report has been prepared by an independent scientific working group. The working group was commissioned by the Health and Safety Authority and the Office of Tobacco Control, Ireland, to identify and report on the degree of consensus that exists among leading international scientific authorities on the question of the hazard and risk posed by environmental tobacco smoke to human health in the workplace. June 2002
This report has been prepared by an independent scientific working group. The working group was commissioned by the Health and Safety Authority and the Office of Tobacco Control, Ireland, to identify and report on the degree of consensus that exists among leading international scientific authorities on the question of the hazard and risk posed by environmental tobacco smoke to human health in the workplace. June 2002
Clinical review of Nicotine replacement therapies
Clinical review of Nicotine Replacement Therapies ABC of smoking cessation. Explains how they work and who should have access to them.
Clinical review of Nicotine Replacement Therapies ABC of smoking cessation. Explains how they work and who should have access to them.
Guidance on NRT and Bupropion (Zyban)
2002/02 National Institute of Clinical Excellence (NICE) recommends use of smoking cessation therapies. NICE gives unequivocal endorsement to the use of Nicotine replacement therapies or Buproprion (Zyban) for smokers who wish to quit.
2002/02 National Institute of Clinical Excellence (NICE) recommends use of smoking cessation therapies. NICE gives unequivocal endorsement to the use of Nicotine replacement therapies or Buproprion (Zyban) for smokers who wish to quit.
Consultation on NRT on prescription launched in Scotland
Scottish Health Minister, Susan Deacon announces a consultation on allowing all NRT products to be prescribed on the NHS.
Scottish Health Minister, Susan Deacon announces a consultation on allowing all NRT products to be prescribed on the NHS.
NICE Technology Appraisal Guidance - Bupropion and NRT
Guidance by National Institute of Clinical Excellence (NICE) Technology Appraisal Guidance No. 38 Smoking cessation - bupropion and nicotine replacement therapy. Technology Appraisal Guidance TGA39 Smoking cessation - bupropion and nicotine replacement therapy. Issue Date: March 2002 Review Date: March 2005
Guidance by National Institute of Clinical Excellence (NICE) Technology Appraisal Guidance No. 38 Smoking cessation - bupropion and nicotine replacement therapy. Technology Appraisal Guidance TGA39 Smoking cessation - bupropion and nicotine replacement therapy. Issue Date: March 2002 Review Date: March 2005
NICE Assessment of clinical and cost effectiveness of Zyban and NRT
This review aims to address the effectiveness, cost-effectiveness and adverse effects of bupropion (Zyban) and nicotine replacement therapy (NRT) for smoking cessation.
This review aims to address the effectiveness, cost-effectiveness and adverse effects of bupropion (Zyban) and nicotine replacement therapy (NRT) for smoking cessation.
Towards smoke-free public places (pdf)
Excellent BMA summary of the science of passive smoking and policy implications for smoking
Excellent BMA summary of the science of passive smoking and policy implications for smoking
